Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan and Ivonescimab in HR+/HER2- Advanced Breast Cancer
NCT07647016Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan, ivonescimab in breast cancer, sponsored by Fudan University. Started Apr 2026; status: recruiting.
02
Drugs
trastuzumab deruxtecanivonescimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07647016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647016.